Tumorigenesis of colorectal cancer cells (CT26, red) were significantly reduced...
Tumorigenesis of colorectal cancer cells (CT26, red) were significantly reduced in mice liver tissue lacking IL-6 (Il6-/-), suggesting IL-6’s supportive function on metastasis.

Image source: Toyoshima Y. et al., Cancer Immunology Research 2019

News • Promising treatment target

"Partner-in-crime" of colorectal cancer discovered

A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target, researchers from Hokkaido University discovered.

Colorectal cancer patients with an immune system-regulating protein called interleukin 6 (IL-6) are more likely to have recurring tumors that can also spread to the liver, according to research published in the journal Cancer Immunology Research. The Hokkaido University investigations into the protein’s role in liver metastasis could help improve colorectal cancer treatment options. Colorectal cancer is the second most common cancer in women and third most common in men. The spreading of this cancer to other organs, most often to the liver, significantly reduces patient survival.

portrait of hidemitsu kitamura
Hidemitsu Kitamura of the Hokkaido University’s Institute for Genetic Medicine.
Source: Hokkaido University

One cancer treatment approach is immune therapy, which stimulates a person’s own immune system to attack tumor sites. However, its effectiveness varies with different cancers and in different people. This suggests that several different mechanisms are working at the same time to suppress the immune systems of those with cancer. Scientists are seeking ways to improve the effectiveness of immune therapy for patients.

Immunologist Hidemitsu Kitamura and colleagues at Japan’s Hokkaido University had previously found IL-6 expression plays a role in suppressing immune response in tumor tissues. They wanted to see if it also helps spread colorectal cancer to the liver. To do this, they used two groups of mice, one in which IL-6 expression was turned off and the other with IL-6 expression turned on. Both groups were inoculated with colorectal cancer cells. They assessed cancer levels in the liver, as well as the effects of IL-6 on different types of immune cells. They also analyzed IL-6 expression in human colorectal cancer patients.

“We hope that targeting IL-6 will be an effective approach to reduce the spread of cancer and improve survival in colorectal cancer patients. This approach could be combined with other immune therapy strategies, such as the one targeting PD-L1, to augment their effects on colorectal cancer in the future,” says Hidemitsu Kitamura.


Source: Hokkaido University

21.02.2020

Read all latest stories

Related articles

Photo

News • Metastatic recurrence

Researchers discover mechanism responsible for colon cancer relapse

Researchers in Barcelona discovered the population of residual tumour cells responsible for the recurrence of colorectal cancer in other organs after removal of the primary tumour.

Photo

News • Oncology & health informatics

Colon cancer: AI tool predicts survival, treatment response

A new artificial intelligence model could bring much-needed clarity to doctors delivering prognoses and deciding on treatments for patients with colorectal cancer.

Photo

News • Pregnancy & colorectal cancer

Colorectal cancer in the mother linked to adverse pregnancy outcomes

In a nationwide Swedish study of 207 births to women with an earlier diagnosis of colorectal cancer (CRC), researchers found an increased risk of both maternal and neonatal adverse outcomes.

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Shimadzu – MALDImini-1

Research Use Only

Shimadzu – MALDImini-1

Shimadzu Europa GmbH
Subscribe to Newsletter